1. Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
- Author
-
Alexis Ogdie, Lars E. Kristensen, Enrique R. Soriano, Servet Akar, Yanhui Sun, David Gruben, Lara Fallon, Cassandra D. Kinch, and Dafna D. Gladman
- Subjects
Ankylosing spondylitis ,Inflammation ,Interventional studies ,JAK inhibitors ,Psoriatic arthritis ,Smoking ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Introduction Routine care studies of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) demonstrated attenuated responses to tumor necrosis factor inhibitors in current/past versus never smokers. This post hoc analysis assessed tofacitinib efficacy and safety in patients with PsA or AS by cigarette smoking status at trial screening. Methods Pooled data from phase 3 and long-term extension (safety only) PsA trials and phase 2 and 3 AS trials were assessed by current/past versus never smoker status. Analysis included efficacy and safety data for tofacitinib 5 (PsA/AS) and 10 (PsA only) mg twice daily (BID) or placebo, and safety data in AS for tofacitinib 2 and 10 mg BID. Efficacy outcomes included American College of Rheumatology ≥ 50% responses (ACR50) and minimal disease activity (MDA) responses to month (M)6/M3 (tofacitinib/placebo) in PsA; and ≥ 40% improvement in Assessment of SpondyloArthritis international Society responses (ASAS40) and AS Disease Activity Score (ASDAS)
- Published
- 2024
- Full Text
- View/download PDF